News & Updates

The investigational oral small-molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA) elecoglipron yields meaningful weight reductions with a safety profile consistent with the drug class, according to a phase 2 dose-ranging study.

Treatment with a once-weekly injectable petrelintide, a novel human amylin analogue, yields up to 10.7 percent weight loss through week 42 in adults with obesity or overweight, according to the phase II ZUPREME-1 trial presented at ADA 2026.

In the phase II VESPER-2 trial, the investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) berobenatide shows robust reductions in weight and HbA1c in adults with obesity/overweight and type 2 diabetes (T2D).

Exposure to several glucose-lowering drugs appears to have a protective effect on the risk of depression in individuals with type 2 diabetes (T2D), according to a population-based cohort study in Hong Kong.

Relative fat mass is strongly associated with incident stroke, especially ischaemic stroke, as shown in a study.

A recent study has noted a broad range of total testosterone levels in older community-dwelling men, with a substantial proportion in a range deemed hypogonadal.

Women with polycystic ovarian syndrome (PCOS) may have an increased risk of thromboembolic events in the presence of obstructive sleep apnoea (OSA), according to a retrospective study.

Cardiometabolic comorbidities have shown improvements following surgery in patients with Cushing syndrome (CS) and those with mild autonomous cortisol secretion (MACS), reports a study.